News
Surveillance and medical protocols are in place, but environmental factors for the epidemic reappearing regularly cannot be ruled out.
How fast does a fish disappear? How long does it take to erase all evidence of its life, to turn it into a fillet? What about ...
Three De-suup trainees, a man and two women, have died at the national referral hospital after a Leptospirosis outbreak at a ...
The report provides a detailed analysis of the current acute respiratory distress syndrome (ARDS) marketed drugs and late-stage pipeline drugs. Inside the ARDS Market | How Tech, Awareness, Rising ...
Abstract and Introduction Background: Over the last decade, several studies have suggested that survival rates for patients with acute lung injury (ALI) or ARDS may have improved. We performed a ...
Over the last 7 days, the United States market has risen by 1.7%, and over the past year, it is up 12%, with earnings forecasted to grow by 15% annually. For investors seeking opportunities beyond ...
Introduction Acute respiratory distress syndrome (ARDS) is a sudden and serious lung injury in the intensive care unit (ICU), which is characterized by deterioration of alveolar-vascular permeability ...
Cardiorenal syndrome (CRS) commonly occurs during treatment of acute decompensated heart failure (ADHF) and is associated with poor clinical outcome. The pathophysiology of CRS entails a complex ...
The R/I ratio showed limited accuracy in predicting lung recruitability in ARDS but reliably identified low recruiters.
NORTH BRUNSWICK, N.J., June 17, 2025 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, announces that the U.S.
In the U.S. alone, ARDS affects over 500,000 patients per year, or roughly 10% of all ICU admissions. With no effective pharmacological therapies currently available for ARDS and its high ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results